A fantastic segment ran on KABC Los Angeles last night entitled "Lung Cancer Strikes Younger Demographic." It was filmed last week at PER®'s International Lung Cancer Congress® and featured interviews with Dr. Barbara Gitlitz, Bonnie J Addario, and 28 year old lung cancer survivor Emily Bennett Taylor.
Click here to watch the video.
Physicians' Education Resource®, LLC, (PER®) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician's Education Resource®, LLC designates this live activity for a maximum of 22.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by educational grants from Amgen Inc., Astellas, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Biodesix Inc., Bristol-Myers Squibb, Celgene Corporation, Clovis Oncology, Genentech, Lilly, and Novartis Pharmaceuticals Corporation.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
PER® also gratefully acknowledges the Bonnie J. Addario Lung Cancer Foundation and the International Association for the Study of Lung Cancer for their support of this CME activity.
As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI.Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multistep process.
The following individuals have no relevant financial relationships with commercial interests to disclose:
Friedrich Knollmann, MD, PhD; Ken Yoneda, MD; Daniel Lieber, MD; Philip Mack, PhD; Ravi Salgia, MD, PhD
The staff of PER®: David Lee, PhD; Ann C. Lichti, CHCP; and Michael Perlmutter, MS, PharmD
The following individuals have relevant financial relationships with commercial interests to disclose:
Paul Baas, MD, PhD - Grant Research Support: Bristol-Myers Squibb, MSD Pharmaceuticals; Consultant: Verastem, MSD Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca, Pfizer; Lyudmila Bazhenova, MD - Consultant: Clovis Pharmaceuticals, Genoptix, Boehringer Ingelheim, Seattle Genetics; Speakers Bureau: Genentech, Pfizer; Shareholder: Epic Sciences; Paul Bunn, Jr, MD - Grant Research Support: AstraZeneca, Eisai; Consultant: AstraZeneca, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi, Eisai, Genentech, Lilly, Merck, Novartis, Clovis; Walter Curran, Jr, MD - Consultant: Bristol-Myers Squibb, AstraZeneca; Shareholder: NantHealth; Roy Decker, MD, PhD - Grant Research Support: Merck & Co, Inc; 21st Century Oncology; Consultant: AMAG Pharmaceuticals, Leidos Biomedical Research, Inc.; Shareholder: Bristol-Myers Squibb; David Gandara, MD - Grant Research Support: Abbott, Bristol-Myers Squibb, ImClone, Genentech, Lilly, Merck, Novartis, Pfizer; Consultant: Amgen, AstraZeneca, Boehringer Ingelheim, BioMarin, Bristol-Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, sanofi-aventis, Response Genetics Inc., Synta Pharmaceuticals; Barabara Gitlitz, MD - Speakers' Bureau: Genentech, Eli Lilly; Glenwood D. Goss, MD, BCh, FCP(SA), FRCPC - Grant Research Support: AstraZeneca; Advisory Board Honoraria: Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, Roche, Pfizer; Roy Herbst, MD, PhD - Grant Research Support: Genentech; Consultant: Ariad Pharmaceuticals, Eli Lilly, Genentech/Roche, Gilead, Merck, Pfizer; Scientific Advisory Boards: Biothera, Diatech, Kolltan, N of 1; Fred Hirsch, MD, PhD - Grant/Research Support: Celgene, Genentech, Ventana, Amgen, ImClone/Lilly; Consultant: Genentech/Roche, Pfizer, Novartis, Celgene, Biodesix, Biothera, Synta; Karen Kelly, MD - Grant Research Support: Millennium, Novartis, Proacta, Lilly, Synta, EMD Serono, Genentech; Consultant: Clovis, Genentech, Lilly, Transgene, Synta, AstraZeneca; Corey Langer, MD, FACP - Grant Research Support: Merck, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, AstraZeneca, Advantagene, Inovio Pharmaceuticals, Nektar, Genentech/Roche, GlaxoSmithKline; Consultant: Abbott, Clovis, Lilly, Genentech/Roche, Boehringer Ingelheim, AstraZeneca/MedImmune, Pfizer; Data and Safety Monitoring Committee, Lilly, Amgen, Peregrine Pharmaceuticals, Synta; Primo Lara, Jr, MD Grant/Research Support: Millennium, Aragon, Janssen, Polaris, OncoGeneX, GlaxoSmithKline, Genentech; Consultant: Janssen, Clovis, Astex, USOS, Exelixis, Immunojen, Pfizer, Teva, Medivation, Novartis, Halozyme, Sanofi, LPath, Lilly; Tony Mok, MD - Consultant: AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck Serono, MSD, Janssen, Clovis Oncology, BioMarin, GlaxoSmithKline, Novartis, SFJ Pharmaceuticals, ACEA Biosciences, Inc; Speakers' Bureau: AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, MSD, Amgen, Janssen, Clovis Oncology, GlaxoSmithKline, Novartis; Shareholder: Sanomics Limited ; Sai-Hong Ignatius Ou, MD, PhD - Grant Research Support: Pfizer, Roche, AstraZeneca, Clovis, Ariad Pharmaceuticals, Ignyta, GlaxoSmithKline; Consultant: Pfizer, Roche; Speakers' Bureau: Roche, Boehringer Ingelheim; Scientific Advisor: Ignyta; Harvey Pass, MD - Grant Research Support: National Cancer Institute, Technion, Centers for Disease Control and Prevention; Consultant: Visiongate; Suresh Ramalingam, MD - Consultant: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Lilly, Genentech, Novartis; Jonathan Riess, MD, MS - Grant Research Support: Merck, Millennium, Onconova Therapeutics, Novartis; Consultant: Celgene; Honoraria: Genentech; Naiyer Rizvi, MD - Consultant: Merck, Roche, Bristol-Myers Squibb, AstraZeneca; Jack Roth, MD, FACS - Grant Research Support: Varian; Consultant: Genprex; Shareholder: Genprex; Patents: Genprex (all held by the University of Texas); Giorgio Scagliotti, MD, PhD - Consultant: Lilly; Speakers' Bureau: Eli Lilly, AstraZeneca, Pfizer, Roche, Clovis Oncology; Everett Vokes, MD - Consultant: AbbVie, AstraZeneca, Boehringer Ingelheim, Celgene, Clovis, Eisai, Eli Lilly, GeneCentric, Genentech, Merck, Synta, Transgene, VentiRx; Heather Wakelee, MD - Grant Research Support: Novartis, Bristol-Myers Squibb, Clovis, Xcovery, Celgene, Roche/Genentech, MedImmune, Pfizer, Lilly; Consultant: Peregrine, Novartis; Ignacio Wistuba, MD - Grant Research Support: CPRIT, Asuragen, DoD, National Institutes of Health/National Cancer Institute, LUNGevity Foundation, Medical Research Foundation, Genentech, University of Michigan; Consultant: Genentech/Roche, Boehringer Ingelheim, National Comprehensive Cancer Network, Bristol-Myers Squibb; Sue Yom, MD, PhD - Grant Research Support: Genentech; Advisory Board Member: DARA BioSciences, Inc.
Information accurate at the time of posting.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.
PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.
Dec 31, 2018
Medical Crossfire®: Defining New Roles for the Application of PARP Inhibition Strategies in Multiple Tumor Types
Dec 31, 2018
Dec 31, 2018